๐Ÿ”ฅ๐Ÿ” BizChicken ๐Ÿ”๐Ÿ”ฅ

Companies Similar to Krystal Biotech, Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Biogen Inc.

Biogen Inc. logo
Market Cap: Highest
Employees: Highest

TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, FAMPYRA, SPINRAZA, FUMADERM, BENEPALI, ADUHELM, IMRALDI, FLIXABI, RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS

Biogen Inc. focuses on discovering, developing, manufacturing, and delivering therapies for neurological and neurodegenerative diseases, including multiple sclerosis, spinal muscular atrophy, plaque psoriasis, Alzheimer's disease, and various cancers and autoimmune conditions.

Tags: biotechnology, multiple sclerosis, neurodegenerative diseases, neurological diseases, pharmaceuticals

Symbol: BIIB

Recent Price: $150.19

Industry: Drug Manufacturers - General

CEO: Mr. Christopher A. Viehbacher

Sector: Healthcare

Employees: 7570

Address: 225 Binney Street, Cambridge, MA 02142

Phone: 617 679 2000

Leadership

  • Christopher A. Viehbacher, President and Chief Executive Officer
  • Susan H. Alexander, Chief Legal Officer
  • Ginger Gregory, Ph.D., Chief Human Resources Officer
  • Jane Grogan, Ph.D., Head of Research
  • Rachid Izzar, Head of Global Product Strategy & Commercialization
  • Adam Keeney, Head of Corporate Development
  • Michael McDonnell, Chief Financial Officer
  • Nicole Murphy, Head of Pharmaceutical Operations and Technology
  • Priya Singhal, M.D., M.P.H., Head of Development and Interim Chief Medical Officer
  • Alisha Alaimo, President, Head of North America
  • Stephen Amato, Head of Investor Relations
  • Natacha Gassenbach, Head of Corporate Affairs, Chief Communications Officer
  • Fraser Hall, President, Head of Intercontinental Region
  • Wolfram Schmidt, President, Head of Europe
  • Kendra Thomas, Head of Global Workforce Diversity, Equity & Inclusion (DE&I)
  • Caroline Dorsa, Chair of the Board
  • Maria C. Freire, Ph.D., Director
  • William A. Hawkins, Director
  • Susan Langer, Director
  • Jesus B. Mantas, Director
  • Lloyd B. Minor, M.D., Director
  • Monish Patolawala, Director
  • Eric K. Rowinsky, M.D., Director
  • Stephen A. Sherwin, M.D., Director

Last updated: 2024-12-31

Genelux Corporation

Genelux Corporation logo
Market Cap: Low
Employees: Lowest

Olvi-Vec

Genelux Corporation is a clinical-stage biopharmaceutical company developing oncolytic viral immunotherapies for tough-to-treat cancers, with a lead product candidate, Olvi-Vec.

Tags: Olvi-Vec, biopharmaceutical, cancer treatment, clinical-stage, oncolytic viral immunotherapies

Symbol: GNLX

Recent Price: $2.40

Industry: Biotechnology

CEO: Mr. Thomas Zindrick J.D.

Sector: Healthcare

Employees: 24

Address: 2625 Townsgate Road, Westlake Village, CA 91361

Phone: 858 483 0024

Leadership

  • Bob Smith, CTO
  • THOMAS ZINDRICK, J.D., Chairman
  • JAMES L. TYREE, MBA, Lead Independent Director
  • MARY MIRABELLI, MBA, Chair, Nominating and Corporate Governance Committee
  • JOHN THOMAS, M.A., MBA, Ph.D., Chair, Audit Committee
  • JOHN SMITHER, Chair, Compensation Committee
  • Alice Johnson, CEO
  • Carol Davis, CFO
  • David Wilson, Chairman
  • Eva Brown, Director

Last updated: 2024-12-31

Kiromic BioPharma, Inc.

Kiromic BioPharma, Inc. logo
Market Cap: Lowest
Employees: Lowest

ALEXIS-ISO-1, ALEXIS-PRO-1

Kiromic Bio Pharma, Inc. is an artificial intelligence-driven allogeneic cell therapy company that develops multi-indication T cell therapies, leveraging the Gamma Delta T cell to target solid tumors. Key products include ALEXIS-ISO-1 and ALEXIS-PRO-1.

Tags: T cell therapies, artificial intelligence, biopharmaceutical, cell therapy, oncology

Symbol: KRBP

Recent Price: $0.93

Industry: Biotechnology

CEO: Mr. Pietro Bersani CPA, J.D.

Sector: Healthcare

Employees: 35

Address: 7707 Fannin, Houston, TX 77054

Phone: 832 968 4888

Leadership

  • Pietro Bersani, CPA, Director
  • Leonardo Mirandola, PhD, Chief Scientific Officer/Interim COO
  • Scott Dahlbeck, MD, PharmD, Chief of Staff
  • Brian Hungerford, Chief Financial Officer
  • Michael Nagel, Chairperson
  • Michael Catlin, Independent Director
  • Pam Misajon, Independent Director

Last updated: 2024-12-31

Vera Therapeutics, Inc.

Vera Therapeutics, Inc. logo
Market Cap: High
Employees: Low

atacicept

Vera Therapeutics, Inc. is a clinical stage biotechnology company focusing on developing and commercializing treatments for serious immunological diseases, including atacicept for immunoglobulin A nephropathy and MAU868 for BK viremia infections.

Tags: MAU868, atacicept, biotechnology, clinical trial, immunological diseases

Symbol: VERA

Recent Price: $42.06

Industry: Biotechnology

CEO: Dr. Marshall W. Fordyce M.D.

Sector: Healthcare

Employees: 72

Address: 8000 Marina Boulevard, Brisbane, CA 94005

Phone: 650 770 0077

Last updated: 2024-12-31

Adverum Biotechnologies, Inc.

Adverum Biotechnologies, Inc. logo
Market Cap: Low
Employees: Low

ADVM-022

Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company focused on developing gene therapy product candidates for the treatment of ocular and rare diseases. Their lead product, ADVM-022, targets chronic retinal conditions such as wet age-related macular degeneration and diabetic macular edema.

Tags: ADVM-022, biotechnology, gene therapy, ocular diseases, rare diseases

Symbol: ADVM

Recent Price: $4.69

Industry: Biotechnology

CEO: Dr. Laurent Fischer

Sector: Healthcare

Employees: 121

Address: 800 Saginaw Drive, Redwood City, CA 94063

Phone: 650 656 9323

Last updated: 2024-12-31

Beam Therapeutics Inc.

Beam Therapeutics Inc. logo
Market Cap: High
Employees: Medium

precision genetic medicines

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States, with a focus on conditions such as sickle cell disease, beta thalassemia, and Glycogen Storage Disease Type Ia.

Tags: Glycogen Storage Disease Type Ia, beta thalassemia, biotechnology, collaboration, genetic medicine, sickle cell disease

Symbol: BEAM

Recent Price: $25.28

Industry: Biotechnology

CEO: Mr. John M. Evans M.B.A.

Sector: Healthcare

Employees: 472

Address: 238 Main Street, Cambridge, MA 02142

Phone: 857 327 8775

Last updated: 2024-12-31

BeiGene, Ltd.

BeiGene, Ltd. logo
Market Cap: Highest
Employees: Highest

BRUKINSA, Tislelizumab, REVLIMID, VIDAZA, XGEVA, BLINCYTO, KYPROLIS, SYLVANT, QARZIBA, Pamiparib, Pobevcy

Bei Gene, Ltd. is a biotechnology company focused on discovering, developing, manufacturing, and commercializing a wide range of medicines globally, specializing in oncology treatments and clinical stage drug candidates.

Tags: Biotechnology, Medicines, Oncology, Pharmaceuticals, Research and Development

Symbol: BGNE

Recent Price: $183.81

Industry: Biotechnology

CEO: Mr. John V. Oyler

Sector: Healthcare

Employees: 10000

Address: 55 Cambridge Parkway, Cambridge, MA 02142

Phone: 781-801-1800

Leadership

  • John V. Oyler, Co-Founder, Chairman and CEO
  • Xiaodong Wang, Ph.D., Co-Founder, Chairman of Scientific Advisory Board
  • Olivier Brandicourt, M.D., Director
  • Margaret Dugan, M.D., Director
  • Donald W. Glazer, Director
  • Michael Goller, Director
  • Anthony Hooper, Director
  • Ranjeev Krishana, Director
  • Michael Nuoqing Yi, Director
  • Alessandro Riva, M.D., Director
  • Corsee Sanders, Ph.D., Director
  • Shalini Sharp, Director
  • Steven Young, Ph.D., Acting Head of Medicinal Chemistry
  • Ron Levy, M.D., Scientific Advisory Board
  • Neal Rosen, M.D., Ph.D., Scientific Advisory Board
  • Charles Sawyers, M.D., Scientific Advisory Board
  • David Schenkein, M.D., Scientific Advisory Board
  • Melika Davis, SVP & Global Head, Clinical Operations
  • Clare Fisher, SVP, Business Development, Licensing, and M&A (ex-China)
  • Tony Guo, Ph.D., SVP, Global Statistics & Data Science
  • Dany Habr, M.D., Head of Medical Affairs, North America & International Markets
  • Graham Hardiman, Global Head of HR
  • Shreya Devendra Jani, SVP, Corporate Affairs
  • Jaspreet Jaggi, M.D., Ph.D., SVP and Head, Clinical Portfolio Strategy
  • Yang Ji, Chief Compliance Officer
  • Mark Lanasa, M.D., Ph.D., SVP, Chief Medical Officer, Solid Tumors
  • Chan Lee, General Counsel
  • Kyu-Sung Lee, Ph.D., SVP, Global Head of Technical Operations and Manufacturing
  • Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer
  • Kyoung Lim, VP of Supply Chain
  • Han Ma, M.D., Ph.D., Chief Safety Officer and SVP, Global Patient Safety
  • Mehrdad Mobasher, M.D., M.P.H., Chief Medical Officer, Hematology
  • Richard Oโ€™Keeffe, Head of Global Quality
  • Jurij Petrin, M.D., Head of New Market Development
  • Yan Qi, Ph.D., SVP, Head of Public Affairs
  • Hongyu Qian, SVP, Medical Affairs
  • Jason Radford, SVP, Strategy & Corporate Development
  • Anand Reddi, VP, Global Strategic Initiatives and Corporate Operations, Chief of Staff to the CEO
  • Adam Roach, VP and Head of Asia Pacific
  • Aaron Rosenberg, Chief Financial Officer
  • Michael Schoen, Strategic Advisor and Special Assistant to the CEO
  • Matt Shaulis, General Manager of North America
  • Lai Wang, Ph.D., Global Head of R&D
  • Zhiwei Wang, Ph.D., SVP, Research Head of Chemistry
  • Beth Wensley, SVP, Head of Portfolio and Program Management
  • Kimberly Wolf, SVP, Global Commercial Strategy & Operations
  • Xiaobin Wu, Ph.D., President, Chief Operating Officer
  • Eva Yin, Chief Commercial Officer, Greater China

Last updated: 2024-12-31

89bio, Inc.

89bio, Inc. logo
Market Cap: Medium
Employees: Low

pegozafermin

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for liver and cardio-metabolic diseases, primarily through its lead product candidate, pegozafermin, designed to treat nonalcoholic steatohepatitis and severe hypertriglyceridemia.

Tags: biopharmaceutical, cardio-metabolic, clinical-stage, hypertriglyceridemia, liver diseases, nonalcoholic steatohepatitis, pegozafermin

Symbol: ETNB

Recent Price: $7.87

Industry: Biotechnology

CEO: Mr. Rohan Palekar

Sector: Healthcare

Employees: 70

Address: 142 Sansome Street, San Francisco, CA 94104

Phone: 415 432 9270

Last updated: 2024-12-31

bluebird bio, Inc.

bluebird bio, Inc. logo
Market Cap: Low
Employees: Medium

betibeglogene autotemcel, lovotibeglogene autotemcel, elivaldogene autotemcel

bluebird bio, Inc. is a biotechnology company that researches, develops, and commercializes transformative gene therapies for severe genetic diseases, including treatments for รŸ-thalassemia, sickle cell disease, and cerebral adrenoleukodystrophy.

Tags: betibeglogene autotemcel, biotechnology, elivaldogene autotemcel, gene therapy, genetic diseases, lovotibeglogene autotemcel

Symbol: BLUE

Recent Price: $7.86

Industry: Biotechnology

CEO: Mr. Andrew Obenshain

Sector: Healthcare

Employees: 375

Address: 60 Binney Street, Cambridge, MA 02142

Phone: 339 499 9300

Leadership

  • Sarah Alspach, Senior Vice President, External Affairs
  • Rich Colvin, MD, PhD, Chief Medical Officer
  • Kasra Kasraian, Senior Vice President, Technical Development and Operations
  • Tom Klima, Chief Commercial & Operating Officer
  • Andrew Obenshain, Chief Executive Officer
  • Scott Shoemaker, Senior Vice President, Quality
  • James Sterling, Chief Financial Officer
  • Joe Vittiglio, Chief Business and Legal Officer
  • Andrea Walton, Chief People Officer
  • Leslie Wilder, Vice President, Head of Regulatory Science
  • Mark Vachon, Chairman; Formerly of GE
  • John O. Agwunobi, M.D., Formerly of Herbalife Nutrition
  • Mike Cloonan, President and Chief Executive Officer, Sionna Therapeutics
  • Charlotte Jones-Burton, M.D., Formerly of Chinook Therapeutics
  • Lis Leiderman, M.D., CHIEF FINANCIAL OFFICER & CORPORATE DEVELOPMENT OFFICER AT DEWPOINT THERAPEUTICS
  • Nick Leschly, Former Chief Kairos Officer, 2seventy Bio
  • Richard Paulson, President and Chief Executive Officer at Karyopharm Therapeutics Inc.
  • Najoh Tita-Reid, Chief Brand and Experience Officer, Mars Petcare

Last updated: 2024-12-31

Benitec Biopharma Inc.

Benitec Biopharma Inc. logo
Market Cap: Low
Employees: Lowest

BB-301 and BB-103

Benitec Biopharma Inc. is a development-stage biotechnology company specializing in DNA-directed RNA interference-based therapeutics for chronic and life-threatening conditions. Its lead products include BB-301 for oculopharyngeal muscular dystrophy and BB-103 for chronic hepatitis B virus infection.

Tags: RNA interference, biotechnology, chronic conditions, gene therapy, genetic medicines, hepatitis B, oculopharyngeal muscular dystrophy

Symbol: BNTC

Recent Price: $12.51

Industry: Biotechnology

CEO: Dr. Jerel A. Banks M.D., Ph.D.

Sector: Healthcare

Employees: 16

Address: 3940 Trust Way, Hayward, CA 94545

Phone: 510 780 0819

Leadership

  • Jerel Banks, M.D., Ph.D., Chief Executive Officer & Chairman of the Board
  • Megan Boston, Executive Director

Last updated: 2024-12-31

Precision BioSciences, Inc.

Precision BioSciences, Inc. logo
Market Cap: Lowest
Employees: Low

ARCUS

Precision Bio Sciences, Inc. is a clinical stage gene editing company specializing in in vivo gene editing and ex vivo allogeneic CAR T therapies, including the ARCUS genome editing platform and various investigational CAR T immunotherapies.

Tags: CAR T therapies, allogeneic CAR T, clinical stage, gene editing, genetic disorders, immunotherapy

Symbol: DTIL

Recent Price: $4.26

Industry: Biotechnology

CEO: Mr. Michael Amoroso

Sector: Healthcare

Employees: 109

Address: 302 East Pettigrew Street, Durham, NC 27701

Phone: 919 314 5512

Last updated: 2024-12-31

Krystal Biotech, Inc.

Krystal Biotech, Inc. logo
Market Cap: High
Employees: Low

beremagene geperpavec (B-VEC)

Krystal Biotech, Inc., a clinical stage biotechnology company, focuses on redosable gene therapy for treating serious rare diseases in the United States, with a pipeline of products at various stages of development.

Tags: biotechnology, clinical stage, gene therapy, rare diseases, redosable gene therapy

Symbol: KRYS

Recent Price: $159.80

Industry: Biotechnology

CEO: Mr. Krish S. Krishnan M.B.A., M.S.

Sector: Healthcare

Employees: 229

Address: 2100 Wharton Street, Pittsburgh, PA 15203

Phone: 412 586 5830

Leadership

  • Krish Krishnan, Board Member
  • Suma Krishnan, Board Member
  • Kathryn Romano, EVP & Chief Accounting Officer
  • Laurent Goux, SVP & General Manager Europe
  • Jennifer McDonough, SVP, Patient Access, Analytics and Operations
  • Christine Wilson, Head of U.S. Sales and Marketing
  • Hiroshi Kasamoto, General Manager Japan
  • David Chien, SVP, Clinical Development
  • Ramesh Arjunji, SVP, Global Value and Access
  • John Thomas, General Counsel & Corporate Secretary
  • Trevor Parry, VP, Research and Scientific Affairs
  • Stรฉphane Paquette, VP, Business Development
  • Mark A. Petrich, VP, Process Development and Validation
  • Felino Obillo, VP, Global Supply Chain
  • Julian Gangolli, Board Member
  • Catherine Mazzacco, Board Member
  • Kirti Ganorkar, Board Member
  • Dino A. Rossi, Board Member
  • Dan Janney, Board Member
  • Chris Mason, Board Member
  • Rand Sutherland, Board Member

Last updated: 2024-12-31

Kintara Therapeutics, Inc.

Kintara Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

VAL-083, REM-001

Kintara Therapeutics is a clinical stage drug development company focused on developing and commercializing anti-cancer therapies for drug-resistant solid tumors.

Tags: REM-001, VAL-083, anti-cancer therapies, clinical stage, drug development

Symbol: KTRA

Recent Price: $0.22

Industry: Biotechnology

CEO: Mr. Jeffrey A. Bacha B.Sc., M.B.A.

Sector: Healthcare

Employees: 1

Address: 12707 High Bluff Drive, San Diego, CA 92130

Phone: 858 350 4364

Leadership

  • Robert E. Hoffman, President, CEO, CFO and Chairman of the Board
  • Greg A. Johnson, (Acting) Head of Operations
  • Laura Johnson, Director
  • Tamara A. Favorito, Director
  • Robert J. Toth, Jr., M.B.A., Director

Last updated: 2024-12-31

Kezar Life Sciences, Inc.

Kezar Life Sciences, Inc. logo
Market Cap: Lowest
Employees: Lowest

KZR-616

Kezar Life Sciences is a clinical-stage biotechnology company focused on developing novel small molecule therapeutics to address unmet needs in immune-mediated diseases and cancer in the United States.

Tags: biotechnology, cancer, clinical trials, immune-mediated diseases, immunoproteasome inhibitor, small molecule therapeutics

Symbol: KZR

Recent Price: $6.82

Industry: Biotechnology

CEO: Dr. Christopher J. Kirk Ph.D.

Sector: Healthcare

Employees: 58

Address: 4000 Shoreline Court, South San Francisco, CA 94080

Phone: 650 822 5600

Leadership

  • Christopher Kirk, PhD, Chief Executive Officer, Co-Founder
  • Marc Belsky, Chief Financial Officer
  • Mark Schiller, Chief Legal Officer
  • Neel K. Anand, DPhil, SVP, Research and Drug Discovery
  • Zung To, SVP, Clinical Development
  • Gitanjali Jain, SVP, Investor Relations and External Affairs
  • Michelle Greenman, VP, Global Regulatory Affairs
  • Jim Kirchner, PhD, VP, CMC and Supply Chain
  • Andrew Basham, VP, Legal Affairs
  • Dave Braggs, VP, Quality Assurance
  • Pattie Chiang, SVP, Corporate Controller
  • Tony Muchamuel, VP, Pharmacology & Toxicology
  • Kiruthi Palaniswamy, PharmD, VP, Medical Affairs
  • Mary Rogers, VP, Financial Planning & Analysis
  • Joe Tedrick, VP, Human Resources
  • Jinhai Wang, PhD, VP, Drug Metabolism & Pharmacokinetics
  • John Fowler, Co-Founder
  • Graham Cooper, Board Member, Beam Therapeutics, Former CFO, Receptos
  • Franklin Berger, Founder
  • Elizabeth Garner, MD, MPH, Chief Science Officer
  • Michael Kauffman, MD, PhD, President, Chief Executive Officer, and Director
  • Micki Klearman, MD, Former Group Medical Director
  • Courtney Wallace, Venture Partner

Last updated: 2024-12-31

Vaxcyte, Inc.

Vaxcyte, Inc. logo
Market Cap: Highest
Employees: Low

VAX-24

Vaxcyte, Inc. is a clinical-stage biotechnology company developing novel protein vaccines for preventing or treating bacterial infectious diseases. Key products include the VAX-24 pneumococcal conjugate vaccine and other candidates targeting antibiotic resistance and periodontitis.

Tags: bacterial infectious diseases, biotechnology, clinical-stage, pharmaceuticals, protein vaccines, vaccines

Symbol: PCVX

Recent Price: $81.99

Industry: Biotechnology

CEO: Mr. Grant E. Pickering M.B.A.

Sector: Healthcare

Employees: 254

Address: 825 Industrial Road, San Carlos, CA 94070

Phone: 650 837 0111

Last updated: 2024-12-31

2seventy bio, Inc.

2seventy bio, Inc. logo
Market Cap: Low
Employees: Low

idecabtagene vicleucel

2seventy bio, Inc. is a cell and gene therapy company focusing on cancer treatment research, development, and commercialization, with products including idecabtagene vicleucel and collaborations with Bristol-Myers Squibb.

Tags: biotechnology, cancer treatment, cell therapy, gene therapy, multiple myeloma

Symbol: TSVT

Recent Price: $2.89

Industry: Biotechnology

CEO: Mr. William D. Baird III, M.B.A.

Sector: Healthcare

Employees: 274

Address: 60 Binney Street, Cambridge, MA 02142

Phone: 339 499 9300

Last updated: 2024-12-31

Vir Biotechnology, Inc.

Vir Biotechnology, Inc. logo
Market Cap: Medium
Employees: Medium

Sotrovimab (VIR-7832), VIR-2218, VIR-3434, VIR-2482, VIR-1111

Vir Biotechnology, Inc. is a commercial-stage immunology company developing therapeutic products to treat and prevent serious infectious diseases, including COVID-19, hepatitis B, influenza A, and HIV.

Tags: COVID-19, HIV, biotechnology, hepatitis B, immunology, infectious diseases, influenza, therapeutics

Symbol: VIR

Recent Price: $7.33

Industry: Biotechnology

CEO: Dr. Marianne De Backer M.B.A., M.Sc., Ph.D.

Sector: Healthcare

Employees: 587

Address: 499 Illinois Street, San Francisco, CA 94158

Phone: 415 906 4324

Leadership

  • Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer and Director
  • Jeff Calcagno, M.D., Executive Vice President and Chief Business Officer
  • Vanina de Verneuil, J.D., Executive Vice President, General Counsel and Corporate Secretary
  • Mika Kakefuda Derynck, M.D., Executive Vice President, Therapeutic Area Head Oncology
  • Mark Eisner, M.D., M.P.H., Executive Vice President and Chief Medical Officer
  • Jenny Gumm, Ed.D., MBA, Executive Vice President, Chief Human Resources Officer
  • Aine Hanly, Ph.D., Executive Vice President and Chief Technology Officer
  • Jason Oโ€™Byrne, MBA, Executive Vice President and Chief Financial Officer
  • Jennifer Eileen Towne, Ph.D., Executive Vice President and Chief Scientific Officer
  • Arran Attridge, Senior Vice President Corporate Communications
  • Antonio Lanzavecchia, M.D., Senior Vice President and Senior Research Fellow
  • Amalio Telenti, M.D, Ph.D., Executive Vice President and Senior Research Fellow

Last updated: 2024-12-31

Verve Therapeutics, Inc.

Verve Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

VERVE-101

Verve Therapeutics, Inc. is a genetic medicines company developing gene editing treatments for cardiovascular diseases, primarily through its lead product VERVE-101.

Tags: VERVE-101, biotechnology, cardiovascular diseases, gene editing, genetic medicines

Symbol: VERV

Recent Price: $5.54

Industry: Biotechnology

CEO: Dr. Sekar Kathiresan M.D.

Sector: Healthcare

Employees: 255

Address: 500 Technology Square, Cambridge, MA 02139

Phone: 617 603 0070

Leadership

  • Andrew Ashe, President, Chief Operating Officer and General Counsel
  • Victoria Bartlett, Vice President, Program and Alliance Management
  • Dan Balian, Associate Director, Supply Chain Management
  • Allen Barrett, Director, Corporate Counsel

Last updated: 2024-12-31

Abeona Therapeutics Inc.

Abeona Therapeutics Inc. logo
Market Cap: Low
Employees: Low

EB-101

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa.

Tags: EB-101, biopharmaceutical, cell therapy, clinical trials, gene therapy, rare genetic diseases

Symbol: ABEO

Recent Price: $5.61

Industry: Biotechnology

CEO: Dr. Vishwas Seshadri M.B.A., Ph.D.

Sector: Healthcare

Employees: 84

Address: 1330 Avenue of the Americas, New York, NY 10019

Phone: 646 813 4701

Last updated: 2024-12-31

BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc. logo
Market Cap: High
Employees: Medium

AG10, BBP-265, BBP-831, BBP-631, Encaleret

Bridge Bio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases, with a pipeline of 30 programs including candidates like AG10, BBP-265, and others in various stages of clinical trials.

Tags: biopharmaceuticals, clinical trials, drug development, genetic diseases

Symbol: BBIO

Recent Price: $27.32

Industry: Biotechnology

CEO: Dr. Neil Kumar Ph.D.

Sector: Healthcare

Employees: 550

Address: 421 Kipling Street, Palo Alto, CA 94301

Phone: 650 391 9740

Last updated: 2024-12-31